Table 2.
Association Between CLEC3B rs13963 and Survival Without Neurological Disease
| Fraction (%) of Carriers of the Minor Allele of CLEC3B rs13963 | ||||||||
|---|---|---|---|---|---|---|---|---|
| Participant Group | Age ≤ 50 | Age = 51–60 | Age = 61–70 | Age = 71–80 | Age = 81–90 | Age > 90 | OR (95% CI) | p Value |
| All participants (N = 1,483) | 79/133 (59.4%) | 92/169 (54.4%) | 170/300 (56.7%) | 161/294 (54.0%) | 245/442 (55.4%) | 91/145 (62.8%) | 1.00 (0.94, 1.07) | .89 |
| Males (N = 649) | 25/44 (56.8%) | 40/65 (61.5%) | 77/124 (62.1%) | 78/134 (58.2%) | 124/218 (56.8%) | 40/64 (62.5%) | 1.00 (0.90, 1.11) | .98 |
| Females (N = 834) | 54/89 (60.7%) | 52/104 (50.0%) | 93/176 (52.8%) | 83/160 (51.9%) | 121/224 (54.0%) | 51/81 (63.0%) | 1.01 (0.93, 1.09) | .85 |
| Carriers of APOE ε4 (N = 404) | 26/43 (60.5%) | 24/41 (58.5%) | 49/79 (62.0%) | 47/78 (60.3%) | 60/117 (51.3%) | 28/46 (62.2%) | 1.07 (0.95, 1.21) | .26 |
| Noncarriers of APOE ε4 (N = 1,073) | 53/90 (58.9%) | 67/127 (52.8%) | 121/221 (54.8%) | 114/216 (52.8%) | 183/320 (57.2%) | 63/99 (63.6%) | 0.98 (0.91, 1.06) | .68 |
| Carriers of APOE ε2 (N = 265) | 11/19 (57.9%) | 11/23 (47.8%) | 21/42 (50.0%) | 29/57 (50.9%) | 43/83 (51.8%) | 22/41 (53.7%) | 1.04 (0.89, 1.22) | .59 |
| Noncarriers of APOE ε2 (N = 1,212) | 68/114 (59.6%) | 80/145 (55.2%) | 149/258 (57.8%) | 132/237 (55.7%) | 200/354 (56.5%) | 69/104 (66.3%) | 1.00 (0.93, 1.07) | .94 |
Notes: OR = odds ratio; CI = confidence interval. ORs, 95% CIs, and p-values result from proportional odds logistic regression models (where the dependent variable was an ordered categorical variable for number of minor alleles of CLEC3B rs13963; 0, 1, or 2, and the independent variable was age at blood draw which was analyzed as a continuous variable) that were adjusted for sex, presence of APOE ε4, and presence of APOE ε2 (analysis of all patients), presence of APOE ε4 and presence of APOE ε2 (analysis of males and females), and sex (analysis for carriers and noncarriers of APOE ε4 and APOE ε2). ORs are interpreted as the multiplicative increase in the odds of a greater number of minor alleles of CLEC3B rs13963 corresponding to each 10-y increase in age at blood draw. The six different age categories were utilized for purposes of presentation only; age was analyzed as a continuous variable in all statistical tests of association. Information was unavailable regarding APOE genotype for six patients.